Publications by Dr. Emory

  • Neurometric Subgroups in Attentional and Affective Disorders and Their Association with Pharmacotherapeutic Outcome
  • By Stephen C. Suffin and W. Hamlin Emory
    Source: Clinical Electroencephalography ©1995 Vol. 26 No. 2

  • Referenced-EEG in the Treatment of Eating Disorders
  • By Mark Schiller, M.D., W. Hamlin Emory, M.D., Stephen C. Suffin, M.D. 2004; Presented at the 44th Annual NCDEU Conference

  • A QEEG Database Method for Predicting Pharmacotherapeutic Outcome in Refractory Major Depressive Disorder
  • By Stephen C. Suffin, M.D.; W. Hamlin Emory, M.D.; Mark J. Schiller, M.D.; Arthur Kling, M.D.
    Source: Journal of American Physicians and Surgeons ©2007 Vol. 12 No. 4

  • An Alternative to Standardized Psychiatric Prescribing
  • By W. Hamlin Emory, M.D.
    published in The Eating Disorder Sourcebook 3rd ed. by Carolyn Costin, M.A., M.Ed., M.F.T. 2007. 291-294.

  • EEG Guidance of Psychopharmacologic Treatment: Multi-site Experience.
  • Schiller MJ, Emory WH, Shaffer J, Hamilton JT, Hoffman DA, Davis A. Suffin SS. (May, 2005).
    Poster No. 10 for 158th Annual Meeting of American Psychiatric Association, Atlanta, GA.

  • Referenced - EEG in the Treatment of Eating Disorders.
  • Emory WH, Schiller M, Suffin SC. (June, 2004)
    Poster Presentation at the 44th Annual Meeting of New Clinical Drug Evaluation Unit (NCDEU). Phoenix, AZ.

  • EEG and QEEG as an Adjunct to Clinical Assessment Predicts Response to Atypical Treatment Options.
  • W. Hamlin Emory, M.D., Mark Shatsky, D.O., C. Wells. B.S.
    Poster Presentation at the 22nd Annual ANPA Conference, Denver, March 2011.

  • Questioning the Risk Profile of Selegiline Hydrochloride.
  • W. Hamlin Emory, M.D., Mark Shatsky, D.O., C. Wells. B.S.
    Poster Presentation at the 164th Annual APA Conference, Honolulu 2011 and Institute on Psychiatric Services Conference, San Francisco, October 2011.

  • QEEG Features & Medicinal Response in Epilepsy
  • W. Hamlin Emory, M.D.
    Presented at the International Pharmaco-EEG Society Symposium on EEG-based Personalized Medicine, New York, N.Y; October 2012.

  • EEG Topography and LORETA Tomography in Neuropathology and Treatment of Genetic Epilepsy EEG
  • W. Hamlin Emory, M.D., Christopher Wells, B.A., Neptune Mizrahi, Ph.D.
    Poster Presentation at the International Conference on Basic and Clinical Multimodal Imaging, Geneva, Switzerland, September 2013.
     
  • Quantitative EEG and Current Source Density Analysis of Combined Antiepileptic Drugs and Dopaminergic Agents in Genetic Epilepsy
  • Emory WH, Wells C, and Mizrahi N. Clin EEG Neurosc. 2015; 46(3): 256-262. doi: 10.1177/1550059414532253
    (Spring 2015)
     
  • Monoamine Oxidase Inhibition in a Patient With Type I Diabetes and Depression
  • Emory H. and Mizrahi, N, 2016 Journal of Diabetes Science and Technology. DOI: 10.1177/1932296816638106
     
  • Glycaemic Control By Monoamine Oxidase Inhibition in a Patient With Type 1 Diabetes
  • Emory H. and Mizrahi, N, 2016 Journal of Diabetes & Vascular Research Disease. DOI: 10.1177/1479164116675492
Latest News

March 2016

Monoamine Oxidase Inhibition in a Patient With Type I Diabetes and Depression Emory H. and Mizrahi, N, // (Journal of Diabetes Science and Technology. DOI: 10.1177/1932296816638106)


January 2016

Dr. Hamlin Emory Speaks in Washington State - Finding and Fixing Unrecognized Brain Differences
https://vimeo.com/154468931



Patient Testimonials